Response to Neoadjuvant Treatment With Anti-Aromatase Anastrozole and Anti-Estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-Sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response.

Trial Profile

Response to Neoadjuvant Treatment With Anti-Aromatase Anastrozole and Anti-Estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-Sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms HORGEN
  • Most Recent Events

    • 14 Jul 2015 Status changed from recruiting to completed, according to results published in the British Journal of Cancer.
    • 14 Jul 2015 Results published in the British Journal of Cancer.
    • 19 Mar 2014 Preliminary results presented at the 9th European Breast Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top